MYLAN PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS INDUSTRIES LTD. et al

Track this case

Case Number:

2:21-cv-13087

Court:

New Jersey

Nature of Suit:

Anti-Trust

Judge:

Julien Xavier Neals

Firms

Companies

Sectors & Industries:

  1. April 13, 2026

    Mylan Can't Revive Copaxone Antitrust Claims Against Teva

    A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.

  2. March 03, 2025

    Teva Should Face Key Copaxone Antitrust Claims, Court Told

    Mylan and pharmaceutical wholesalers should be allowed to proceed with some, but not all, parallel claims accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment, a special master has recommended in New Jersey federal court.

  3. November 22, 2021

    Teva Says Mylan Is Just Unhappy About MS Drug Competition

    Teva Pharmaceuticals has urged a New Jersey federal court to toss a suit from Mylan accusing the generic-drug giant of an illegal scheme to stifle competition to its multiple sclerosis treatment, arguing that Mylan is just misplacing blame for its own disappointment.